SCHEMBL178544

SCHEMBL178544

CNC(C)c1ccc(F)c(F)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.41
CES2 O00748 1/20 0.39
CES1 P23141 1/20 0.39
PDPK1 O15530 1/20 0.39
MME P08473 1/20 0.38
ADRB1 P08588 1/20 0.37
ADRA2A P08913 1/20 0.37
ADRB3 P13945 1/20 0.37
ADRA2B P18089 1/20 0.37
ADRA2C P18825 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.36
MAPK1 P28482 4/20 0.36
F10 P00742 2/20 0.35
CHRNA1 P02708 1/20 0.35
CHRNG P07510 1/20 0.35
CHRNB1 P11230 1/20 0.35
CHRNB2 P17787 1/20 0.35
SLC6A2 P23975 1/20 0.35
CHRNB4 P30926 1/20 0.35
CHRNA3 P32297 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8354107 1.00 ALDH1A1 (0.41) ALDH1A1CES2CES1PDPK1MME
SCHEMBL13267451 1.00 ALDH1A1 (0.41) ALDH1A1CES2CES1PDPK1MME
SCHEMBL2669160 0.83 AKR1C3 (0.43) ALDH1A1AKR1C3AKR1C2MEN1KMT2A
SCHEMBL12906685 0.83 ALDH1A1 (0.39) ALDH1A1ADRB1ADRA2AADRB3ADRA2B
SCHEMBL15107742 0.83 AKR1C3 (0.43) ALDH1A1AKR1C3AKR1C2MEN1KMT2A
SCHEMBL15419067 0.82 SLC6A4 (0.47) ALDH1A1MAPK1SLC6A2SLC6A3HTR2A
SCHEMBL20376508 0.82 ADRB1 (0.57) ALDH1A1ADRB1ADRA2AADRB3ADRA2B
SCHEMBL10087245 0.82 GPR139 (0.40) ALDH1A1HTR2ASLC6A4KCNH2GPR139
SCHEMBL178506 0.82 SLC6A4 (0.47) ALDH1A1MAPK1SLC6A2SLC6A3HTR2A
SCHEMBL10315766 0.81 CES2 (0.38) CES2CES1PDPK1MMEADRB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3466929-B1 HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS MILLENNIUM PHARM INC (US) 2023-09-06 EP disclosed
US-8883824-B2 3-(4-aminophenyl)-2-furancarboxylic acid derivative and pharmaceutically acceptable salt thereof SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2014-11-11 US disclosed
EP-2121617-B1 CB1 RECEPTOR MODULATORS 7TM PHARMA AS (DK) 2014-01-22 EP disclosed
US-8426359-B2 Inhibitors of serine proteases, particularly HCV NS3-NS4A protease VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-04-23 US disclosed
US-20120059012-A1 3-(4-AMINOPHENYL)-2-FURANCARBOXYLIC ACID DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-03-08 US disclosed
US-8124634-B2 CB1 receptor modulators 7TM PHARMA A/S (DK) 2012-02-28 US disclosed
US-20100010061-A1 CB1 RECEPTOR MODULATORS 7TM PHARMA A/S (DK) 2010-01-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120059012-A1 3-(4-AMINOPHENYL)-2-FURANCARBOXYLIC ACID DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF ACSL3, SLCO4C1, SLC38A7 ALDH1A1 96/4885CES2 359/4885CES1 886/4885
US-20100010061-A1 CB1 RECEPTOR MODULATORS CNR1, CNR2, GPR6 ALDH1A1 3325/4885CES2 500/4885CES1 312/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.